JP5339227B2 - アクロレイン、インターロイキン−６及びｃｒｐの含有量、ポリアミンオキシダーゼ活性又はポリアミンオキシダーゼの蛋白質量、並びに、被験者の年齢を指標とした脳卒中・無症候性脳梗塞の検出方法 - Google Patents

アクロレイン、インターロイキン−６及びｃｒｐの含有量、ポリアミンオキシダーゼ活性又はポリアミンオキシダーゼの蛋白質量、並びに、被験者の年齢を指標とした脳卒中・無症候性脳梗塞の検出方法 Download PDF

Info

Publication number
JP5339227B2
JP5339227B2 JP2007132239A JP2007132239A JP5339227B2 JP 5339227 B2 JP5339227 B2 JP 5339227B2 JP 2007132239 A JP2007132239 A JP 2007132239A JP 2007132239 A JP2007132239 A JP 2007132239A JP 5339227 B2 JP5339227 B2 JP 5339227B2
Authority
JP
Japan
Prior art keywords
polyamine oxidase
acrolein
interleukin
cerebral infarction
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007132239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008286651A5 (cg-RX-API-DMAC7.html
JP2008286651A (ja
Inventor
一衛 五十嵐
信重郎 並木
円 吉田
Original Assignee
国立大学法人 千葉大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人 千葉大学 filed Critical 国立大学法人 千葉大学
Priority to JP2007132239A priority Critical patent/JP5339227B2/ja
Priority to EP08711525A priority patent/EP2163645B1/en
Priority to PCT/JP2008/052701 priority patent/WO2008142888A1/ja
Priority to US12/598,125 priority patent/US20100167322A1/en
Publication of JP2008286651A publication Critical patent/JP2008286651A/ja
Publication of JP2008286651A5 publication Critical patent/JP2008286651A5/ja
Application granted granted Critical
Publication of JP5339227B2 publication Critical patent/JP5339227B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2007132239A 2007-05-18 2007-05-18 アクロレイン、インターロイキン−６及びｃｒｐの含有量、ポリアミンオキシダーゼ活性又はポリアミンオキシダーゼの蛋白質量、並びに、被験者の年齢を指標とした脳卒中・無症候性脳梗塞の検出方法 Expired - Fee Related JP5339227B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007132239A JP5339227B2 (ja) 2007-05-18 2007-05-18 アクロレイン、インターロイキン−６及びｃｒｐの含有量、ポリアミンオキシダーゼ活性又はポリアミンオキシダーゼの蛋白質量、並びに、被験者の年齢を指標とした脳卒中・無症候性脳梗塞の検出方法
EP08711525A EP2163645B1 (en) 2007-05-18 2008-02-19 Method of detecting cerebral stroke or asymptomatic cerebral infarction using acrolein, interleukin-6 and crp contents, polyamine oxidase activity or polyamine oxidase protein content and subject's age as indications
PCT/JP2008/052701 WO2008142888A1 (ja) 2007-05-18 2008-02-19 アクロレイン、インターロイキン－６及びcrpの含有量、ポリアミンオキシダーゼ活性又はポリアミンオキシダーゼの蛋白質量、並びに、被験者の年齢を指標とした脳卒中・無症候性脳梗塞の検出方法
US12/598,125 US20100167322A1 (en) 2007-05-18 2008-02-19 Method of detecting cerebral stroke or asymptomatic cerebral infarction using acrolein, interleukin-6 and crp contents, polyamine oxidase activity or polyamine oxidase protein content and subject's age as indicators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007132239A JP5339227B2 (ja) 2007-05-18 2007-05-18 アクロレイン、インターロイキン−６及びｃｒｐの含有量、ポリアミンオキシダーゼ活性又はポリアミンオキシダーゼの蛋白質量、並びに、被験者の年齢を指標とした脳卒中・無症候性脳梗塞の検出方法

Publications (3)

Publication Number Publication Date
JP2008286651A JP2008286651A (ja) 2008-11-27
JP2008286651A5 JP2008286651A5 (cg-RX-API-DMAC7.html) 2010-07-01
JP5339227B2 true JP5339227B2 (ja) 2013-11-13

Family

ID=40031607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007132239A Expired - Fee Related JP5339227B2 (ja) 2007-05-18 2007-05-18 アクロレイン、インターロイキン−６及びｃｒｐの含有量、ポリアミンオキシダーゼ活性又はポリアミンオキシダーゼの蛋白質量、並びに、被験者の年齢を指標とした脳卒中・無症候性脳梗塞の検出方法

Country Status (4)

Country Link
US (1) US20100167322A1 (cg-RX-API-DMAC7.html)
EP (1) EP2163645B1 (cg-RX-API-DMAC7.html)
JP (1) JP5339227B2 (cg-RX-API-DMAC7.html)
WO (1) WO2008142888A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2012067150A1 (ja) * 2010-11-16 2014-05-12 三菱化学株式会社 Ｉｎｔｅｒｌｅｕｋｉｎ−６ｒｅｃｅｐｔｏｒｓｕｂｕｎｉｔｂｅｔａ蛋白質による脳梗塞の検査方法
JP6499342B2 (ja) * 2018-03-19 2019-04-10 隆樹 日和佐 脳梗塞の診断マーカー

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3081043B2 (ja) * 1991-12-27 2000-08-28 シスメックス株式会社 脳梗塞の診断方法
JP3609014B2 (ja) 2000-09-22 2005-01-12 善行 澤田 気体溶解装置
DE60233949D1 (de) 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
JP4426929B2 (ja) * 2004-03-25 2010-03-03 株式会社アミンファーマ研究所 脳卒中・無症候性脳梗塞のスクリーニング方法

Also Published As

Publication number Publication date
EP2163645B1 (en) 2012-09-26
JP2008286651A (ja) 2008-11-27
WO2008142888A1 (ja) 2008-11-27
EP2163645A4 (en) 2010-07-21
EP2163645A1 (en) 2010-03-17
US20100167322A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
Teeuw et al. Diagnostic accuracy of urine dipstick tests for proteinuria in pregnant women suspected of preeclampsia: A systematic review and meta-analysis
Tegethoff et al. TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study
Renata et al. Urinary concentration of cytokines in children with acute pyelonephritis
AU2002220029A1 (en) Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker
EP1340078A2 (en) Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrin as a marker
WO2010143423A1 (ja) 糖尿病性腎症の検査方法
WO2020252206A1 (en) Methods for evaluation and treatment of alzheimer's disease and applications thereof
JP2008509411A (ja) 肝線維症の診断方法
Ge et al. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis
Usui et al. Serum uromodulin is a novel renal function marker in the Japanese population
Aoyama et al. Changes of leucine-rich alpha 2 glycoprotein could be a marker of changes of endoscopic and histologic activity of ulcerative colitis
Nakajima et al. β2‐Microglobulin and Neutrophil Gelatinase‐Associated Lipocalin, Potential Novel Urine Biomarkers in Periodontitis: A Cross‐Sectional Study in Japanese
Nishino et al. Article reviewed: plasma orexin-A is lower in patients with narcolepsy
JP2021510815A (ja) 歯周炎の診断方法、使用及びキット
JP2008286651A (ja) アクロレイン、インターロイキン−６及びｃｒｐの含有量、ポリアミンオキシダーゼ活性又はポリアミンオキシダーゼの蛋白質量、並びに、被験者の年齢を指標とした脳卒中・無症候性脳梗塞の検出方法
Mateo et al. Development and evaluation of a rapid and sensitive homogeneous assay for haptoglobin measurements in saliva
WO2006015873A1 (en) Method for diagnosing liver fibrosis
JP4426929B2 (ja) 脳卒中・無症候性脳梗塞のスクリーニング方法
Ostovar et al. Assessment of the diagnostic validities of serum NGAL, KIM-1, and L-FABP in patients with chronic kidney disease
CN111065922A (zh) 肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标
CN103210312A (zh) 通过软骨酸性蛋白1 检测脑梗塞的方法
JP6220222B2 (ja) 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品
US20090011431A1 (en) Diagnosis of Sepsis by the Selective Determination of the Concentration of Cu/Zn Superoxide Dismutase (Cu/Zn Sod) in Patient Samples
US20240418732A1 (en) Biomarkers for diagnosing tuberculosis
EP4553173A1 (en) Markers for detecting and monitoring liver fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130726

R150 Certificate of patent or registration of utility model

Ref document number: 5339227

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees